PLEASANTON, Calif.,
Jan. 21, 2022 /PRNewswire/ -- 10x
Genomics (Nasdaq: TXG), a life sciences leader focused on mastering
biology to advance human health, today announced the expansion of
its 10x Certified Service Provider (CSP) Network to include three
leading clinical research organizations (CROs). The organizations
will partner with 10x Genomics to support global biopharmaceutical
companies seeking to leverage 10x Genomics' robust single-cell and
spatial technologies to power new therapeutic discoveries and
accelerate drug development. The three organizations selected
for the 10x Genomics program are Q2 Solutions, Azenta
Life Sciences, and CellCarta.
![10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.) 10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)](https://mma.prnewswire.com/media/1700607/10x_Genomics_Logo.jpg)
"10x Genomics' single-cell and spatial technologies are trusted
by leading biotechs and the top 20 global pharmaceutical companies
to provide actionable insights at every stage of drug discovery and
development," said Brad Crutchfield,
chief commercial officer of 10x Genomics. "Our biopharmaceutical
customers recognize the significant impact and value of single-cell
and spatial analysis and have asked for more support incorporating
multiomics into their large-scale, correlative studies and clinical
trials. We are excited to partner with Q2 Solutions,
Azenta Life Sciences, and CellCarta. We are confident their
workflow expertise, proven track record with large-scale clinical
trials, and global sample acquisition and management capabilities
will meaningfully benefit our pharmaceutical customers around the
world."
Incorporating single-cell and spatial capabilities into
large-scale clinical research studies can help biopharmaceutical
companies predict resistance to therapies in cancer patients,
analyze end-point molecular readouts in cancer trials, understand
correlative immunological responses to drug therapies, or examine
the molecular mechanisms behind vaccine-elicited cell-mediated
immunity, among other applications.
The 10x Genomics CRO Program requires a rigorous evaluation of
each applicant's capabilities, comprehensive training and a yearly
recertification to ensure designated partners meet and maintain a
high standard of performance and service excellence. All three
global CRO partners bring their own unique expertise to the
program:
Q2 Solutions
Q2 Solutions, an IQVIA company, is a leading
global clinical trial laboratory services organization that
provides comprehensive testing, project management, supply chain,
biorepository, biospecimen, and consent tracking solutions.
Leveraging next generation technologies, Q2 Solutions
delivers agile and precise services designed to meet the diverse
needs of clients. Q2 Solutions provides scientific
expertise and innovative solutions for ADME, bioanalytical,
genomics, vaccines, and central laboratory services, including flow
cytometry, anatomic pathology, immunoassay, molecular and companion
diagnostics, with meticulous regional and global clinical trial
implementation support and high-quality data delivery.
Q2 Solutions genomics laboratory services include
single-cell gene expression, immune profiling (TCR, BCR),
high-throughput sequencing, gene expression profiling and
genotyping studies. Q2 Solutions' professionals have
real-world insight into regulations, customs and sample
requirements to help navigate customers' products through a global,
local or regional trial.
"We are honored to be selected by 10x Genomics as a leading CRO
in their Certified Service Provider Network," said Kellie Yarnell, vice president of genomic
laboratories for Q2 Solutions. "Being a provider in this
program facilitates the ongoing support we are providing to our
clients using 10x single-cell sequencing technology, which has been
well received as an addition to our innovative Genomics portfolio
that accelerates clinical research and development."
Azenta Life Sciences
Azenta Life Sciences is a leading provider of life sciences
solutions worldwide, enabling impactful breakthroughs and therapies
to get to market faster. Azenta provides a full suite of reliable
cold-chain sample management solutions and genomic services across
areas such as drug development, clinical research, and advanced
cell therapies for the industry's top pharmaceutical, biotech,
academic, and healthcare institutions globally. Azenta Life
Sciences was an early adopter of the 10x Genomics single-cell
technologies with extensive experience across many sample types,
established protocols for isolating nuclei, dissociating cells, and
processing less-than-ideal samples. Azenta's experience, global
footprint and complete end-to-end workflow -- from sample sourcing,
numerous genomics and proteomics analysis -- is an excellent fit
for the 10x Genomics CRO Program.
"We are excited to partner with 10x Genomics as we become one of
the first organizations selected for their expanded Certified
Service Provider Network for biopharmaceutical customers," said
Ginger Zhou, vice president of
genomic services and solutions for Azenta Life Sciences. "Azenta
was also one of the first commercial providers to offer 10x
Genomics' services in 2017 and, since that time, has supported
numerous academic and biopharma researchers in their important
work. We look forward to continuing to leverage our extensive
experience in supporting single-cell research and clinical
trial-based customers with this new initiative."
CellCarta
"We're excited to be part of the 10x Genomics Certified Service
Provider Network," said Jurgen Del
Favero, global head of genomics services at CellCarta.
"Offering this latest innovation in single-cell and spatial
analysis reflects our commitment to further support our clients
with their precision medicine needs."
CellCarta is a leading provider of specialized precision
medicine laboratory services to the biopharmaceutical industry.
Leveraging its integrated analytical platforms in immunology,
histopathology, proteomics and genomics, as well as related
specimen collection and logistics services, CellCarta supports the
entire drug development cycle, from discovery to late-stage
clinical trials. The company operates globally with 11 facilities
located in Canada, the U.S.,
Belgium, Australia, and China.
Since its launch in 2018, the 10x Genomics Certified Service
Provider program has expanded to include more than 40 global or
regional service providers and laboratories. For more on the 10x
Certified Service Provider Network, please visit
10xgenomics.com/service-providers.
About 10x Genomics
10x Genomics is a life science technology company building products
to interrogate, understand and master biology to advance human
health. The company's integrated solutions include instruments,
consumables and software for analyzing biological systems at a
resolution and scale that matches the complexity of biology. 10x
Genomics products have been adopted by researchers around the world
including in all of the top 100 global research institutions as
ranked by Nature in 2020 based on publications and all of the top
20 global pharmaceutical companies by 2020 research and development
spend and have been cited in over 3,250 research papers on
discoveries ranging from oncology to immunology and neuroscience.
The company's patent portfolio comprises more than 1,300 issued
patents and patent applications.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange
Commission, its website (www.10xgenomics.com), press releases,
public conference calls, public webcasts and its social media
accounts as means of disclosing material non-public information and
for complying with its disclosure obligations under Regulation
FD.
CONTACTS:
10x Genomics - Media
Media@10xgenomics.com
10x Genomics - Investors
Investors@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-adds-global-clinical-research-organizations-to-expanded-certified-service-provider-network-301465533.html
SOURCE 10x Genomics, Inc.